159 related articles for article (PubMed ID: 18446462)
21. Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles.
Tahvanainen M; Rotko T; Mäkilä E; Santos HA; Neves D; Laaksonen T; Kallonen A; Hämäläinen K; Peura M; Serimaa R; Salonen J; Hirvonen J; Peltonen L
Int J Pharm; 2012 Jan; 422(1-2):125-31. PubMed ID: 22063301
[TBL] [Abstract][Full Text] [Related]
22. A pilot human pharmacokinetic study and influence of formulation factors on orodispersible tablet incorporating meloxicam solid dispersion using factorial design.
Aboelwafa AA; Fahmy RH
Pharm Dev Technol; 2012; 17(1):1-14. PubMed ID: 20550483
[TBL] [Abstract][Full Text] [Related]
23. NEW METHODOLOGY FOR DEVELOPMENT OF ORODISPERSIBLE TABLETS USING HIGH-SHEAR GRANULATION PROCESS.
Ali BE; Al-Shedfat RI; Fayed MH; Alanazi FK
Acta Pol Pharm; 2017 May; 74(3):969-981. PubMed ID: 29513967
[TBL] [Abstract][Full Text] [Related]
24. A novel and discriminative method of in vitro disintegration time for preparation and optimization of taste-masked orally disintegrating tablets of carbinoxamine maleate.
Liu Y; Li P; Qian R; Sun T; Fang F; Wang Z; Ke X; Xu B
Drug Dev Ind Pharm; 2018 Aug; 44(8):1317-1327. PubMed ID: 29521132
[TBL] [Abstract][Full Text] [Related]
25. QbD approach of rapid disintegrating tablets incorporating indomethacin solid dispersion.
Sammour OA; Hammad MA; Zidan AS; Mowafy AG
Pharm Dev Technol; 2011 Jun; 16(3):219-27. PubMed ID: 20163325
[TBL] [Abstract][Full Text] [Related]
26. Taste-masked and affordable donepezil hydrochloride orally disintegrating tablet as promising solution for non-compliance in Alzheimer's disease patients.
Liew KB; Tan YT; Peh KK
Drug Dev Ind Pharm; 2015 Apr; 41(4):583-93. PubMed ID: 24495273
[TBL] [Abstract][Full Text] [Related]
27. Development of Pediatric Orodispersible Tablets Based on Efavirenz as a New Therapeutic Alternative.
de Freitas Neto JL; do Nascimento Gomes Barbosa I; de Melo CG; Ângelos MA; Dos Santos Mendes LM; Ferreira MRA; Rolim LA; Soares LAL; da Silva RMF; Neto PJR
Curr HIV Res; 2020; 18(5):342-353. PubMed ID: 32614748
[TBL] [Abstract][Full Text] [Related]
28. Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization.
Ibrahim HK; El-Setouhy DA
AAPS PharmSciTech; 2010 Mar; 11(1):189-96. PubMed ID: 20112137
[TBL] [Abstract][Full Text] [Related]
29. Formulation and optimization of orodispersible tablets of flutamide.
Elkhodairy KA; Hassan MA; Afifi SA
Saudi Pharm J; 2014 Jan; 22(1):53-61. PubMed ID: 24493974
[TBL] [Abstract][Full Text] [Related]
30. Optimal Design, Characterization and Preliminary Safety Evaluation of an Edible Orodispersible Formulation for Pediatric Tuberculosis Pharmacotherapy.
Matawo N; Adeleke OA; Wesley-Smith J
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784947
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of co-processed excipients used for direct compression of orally disintegrating tablets (ODT) using novel disintegration apparatus.
Brniak W; Jachowicz R; Krupa A; Skorka T; Niwinski K
Pharm Dev Technol; 2013; 18(2):464-74. PubMed ID: 22881600
[TBL] [Abstract][Full Text] [Related]
32. Development and evaluation of novel antihypertensive orodispersible tablets.
Khan HU; Hanif M; Sarfraz RM; Maheen S; Afzal S; Sher M; Afzal K; Mahmood A; Shamim A
Pak J Pharm Sci; 2017 Sep; 30(5):1557-1565. PubMed ID: 29084673
[TBL] [Abstract][Full Text] [Related]
33. Formulation and development of orodispersible sustained release tablet of domperidone.
Patil HG; Tiwari RV; Repka MA; Singh KK
Drug Dev Ind Pharm; 2016; 42(6):906-15. PubMed ID: 26472165
[TBL] [Abstract][Full Text] [Related]
34. Formulation and evaluation of fast dissolving tablets of cinnarizine using superdisintegrant blends and subliming material.
Basu B; Bagadiya A; Makwana S; Vipul V; Batt D; Dharamsi A
J Adv Pharm Technol Res; 2011 Oct; 2(4):266-73. PubMed ID: 22247895
[TBL] [Abstract][Full Text] [Related]
35. Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers.
Yehia SA; El-Ridi MS; Tadros MI; El-Sherif NG
Pharm Dev Technol; 2015; 20(5):528-39. PubMed ID: 24490806
[TBL] [Abstract][Full Text] [Related]
36. Formulation studies for mirtazapine orally disintegrating tablets.
Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Ünlü N
Drug Dev Ind Pharm; 2016; 42(6):1008-17. PubMed ID: 26530146
[TBL] [Abstract][Full Text] [Related]
37. Development of Oral Flexible Tablet (OFT) Formulation for Pediatric and Geriatric Patients: a Novel Age-Appropriate Formulation Platform.
Chandrasekaran P; Kandasamy R
AAPS PharmSciTech; 2017 Aug; 18(6):1972-1986. PubMed ID: 27921260
[TBL] [Abstract][Full Text] [Related]
38. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
Mostafa HF; Ibrahim MA; Sakr A
Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
[TBL] [Abstract][Full Text] [Related]
39. Lallemantia reylenne seeds as superdisintegrant: Formulation and evaluation of nimesulide orodispersible tablets.
Malik K; Arora G; Singh I; Arora S
Int J Pharm Investig; 2011 Jul; 1(3):192-8. PubMed ID: 23071942
[TBL] [Abstract][Full Text] [Related]
40. Amoxicillin chewable tablets intended for pediatric use: formulation development, stability evaluation and taste assessment.
Synaridou MS; Monou PK; Zacharis CK; Fatouros DG; Panderi I; Markopoulou CK
Pharm Dev Technol; 2021 Nov; 26(9):978-988. PubMed ID: 34387136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
